340 related articles for article (PubMed ID: 28483778)
1. Mechanisms and Predictions of Drug-Drug Interactions of the Hepatitis C Virus Three Direct-Acting Antiviral Regimen: Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir.
Shebley M; Liu J; Kavetskaia O; Sydor J; de Morais SM; Fischer V; Nijsen MJMA; Bow DAJ
Drug Metab Dispos; 2017 Jul; 45(7):755-764. PubMed ID: 28483778
[TBL] [Abstract][Full Text] [Related]
2. Drug-Drug Interaction of Omeprazole With the HCV Direct-Acting Antiviral Agents Paritaprevir/Ritonavir and Ombitasvir With and Without Dasabuvir.
Polepally AR; Dutta S; Hu B; Podsadecki TJ; Awni WM; Menon RM
Clin Pharmacol Drug Dev; 2016 Jul; 5(4):269-77. PubMed ID: 27310328
[TBL] [Abstract][Full Text] [Related]
3. Drug-Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy Volunteers.
Polepally AR; King JR; Ding B; Shuster DL; Dumas EO; Khatri A; Chiu YL; Podsadecki TJ; Menon RM
Clin Pharmacokinet; 2016 Aug; 55(8):1003-14. PubMed ID: 26895022
[TBL] [Abstract][Full Text] [Related]
4. Drug-Drug Interactions between Sofosbuvir and Ombitasvir-Paritaprevir-Ritonavir with or without Dasabuvir.
King JR; Dutta S; Cohen D; Podsadecki TJ; Ding B; Awni WM; Menon RM
Antimicrob Agents Chemother; 2016 Feb; 60(2):855-61. PubMed ID: 26596948
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and safety of co-administered paritaprevir plus ritonavir, ombitasvir, and dasabuvir in hepatic impairment.
Khatri A; Menon RM; Marbury TC; Lawitz EJ; Podsadecki TJ; Mullally VM; Ding B; Awni WM; Bernstein BM; Dutta S
J Hepatol; 2015 Oct; 63(4):805-12. PubMed ID: 26070406
[TBL] [Abstract][Full Text] [Related]
6. Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection.
Klibanov OM; Gale SE; Santevecchi B
Ann Pharmacother; 2015 May; 49(5):566-81. PubMed ID: 25680759
[TBL] [Abstract][Full Text] [Related]
7. Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir.
Krishnan P; Tripathi R; Schnell G; Reisch T; Beyer J; Irvin M; Xie W; Larsen L; Cohen D; Podsadecki T; Pilot-Matias T; Collins C
Antimicrob Agents Chemother; 2015 Sep; 59(9):5445-54. PubMed ID: 26100711
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors.
Khatri A; Dutta S; Wang H; Podsadecki T; Trinh R; Awni W; Menon R
Clin Infect Dis; 2016 Apr; 62(8):972-9. PubMed ID: 26740513
[TBL] [Abstract][Full Text] [Related]
9. Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection.
Martinello M; Bhagani S; Gane E; Orkin C; Cooke G; Dore GJ; Petoumenos K; Applegate TL; Tu E; Marks P; Pagani N; Grebely J; Nelson M; Matthews GV
J Viral Hepat; 2018 Oct; 25(10):1180-1188. PubMed ID: 29660224
[TBL] [Abstract][Full Text] [Related]
10. Drug-Drug Interaction between the Direct-Acting Antiviral Regimen of Ombitasvir-Paritaprevir-Ritonavir plus Dasabuvir and the HIV Antiretroviral Agent Dolutegravir or Abacavir plus Lamivudine.
Khatri A; Trinh R; Zhao W; Podsadecki T; Menon R
Antimicrob Agents Chemother; 2016 Oct; 60(10):6244-51. PubMed ID: 27503645
[TBL] [Abstract][Full Text] [Related]
11. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir.
Menon RM; Badri PS; Wang T; Polepally AR; Zha J; Khatri A; Wang H; Hu B; Coakley EP; Podsadecki TJ; Awni WM; Dutta S
J Hepatol; 2015 Jul; 63(1):20-9. PubMed ID: 25646891
[TBL] [Abstract][Full Text] [Related]
12. Mechanistic Evaluation of the Complex Drug-Drug Interactions of Maraviroc: Contribution of Cytochrome P450 3A, P-Glycoprotein and Organic Anion Transporting Polypeptide 1B1.
Kimoto E; Vourvahis M; Scialis RJ; Eng H; Rodrigues AD; Varma MVS
Drug Metab Dispos; 2019 May; 47(5):493-503. PubMed ID: 30862625
[TBL] [Abstract][Full Text] [Related]
13. Managing drug-drug interactions with new direct-acting antiviral agents in chronic hepatitis C.
Talavera Pons S; Boyer A; Lamblin G; Chennell P; Châtenet FT; Nicolas C; Sautou V; Abergel A
Br J Clin Pharmacol; 2017 Feb; 83(2):269-293. PubMed ID: 27530469
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic Evaluation of Darunavir Administered Once or Twice Daily in Combination with Ritonavir or the Three-Direct-Acting Antiviral Regimen of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults Coinfected with Hepatitis C and Human Immunodeficiency Viruses.
King JR; Khatri A; Trinh R; Viani RM; Ding B; Zha J; Menon R
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27919899
[TBL] [Abstract][Full Text] [Related]
15. Exposure-Efficacy Analyses of Ombitasvir, Paritaprevir/Ritonavir with Dasabuvir ± Ribavirin in HCV Genotype 1-Infected Patients.
Khatri A; Mensing S; Podsadecki T; Awni W; Menon R; Dutta S
Clin Drug Investig; 2016 Aug; 36(8):625-35. PubMed ID: 27153823
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir in Healthy Chinese Subjects and HCV GT1b-Infected Chinese, South Korean and Taiwanese Patients.
Zha J; Ding B; Wang H; Zhao W; Yu C; Alves K; Mobashery N; Luo Y; Menon RM
Eur J Drug Metab Pharmacokinet; 2019 Feb; 44(1):43-52. PubMed ID: 29909549
[TBL] [Abstract][Full Text] [Related]
17. Exposure-Safety Response Relationship for Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: Analysis of Data from Five Phase II and Six Phase III Studies.
Lin CW; Menon R; Liu W; Podsadecki T; Shulman N; DaSilva-Tillmann B; Awni W; Dutta S
Clin Drug Investig; 2017 Jul; 37(7):647-657. PubMed ID: 28378135
[TBL] [Abstract][Full Text] [Related]
18. Managing Drug-Drug Interaction Between Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Mycophenolate Mofetil.
Lemaitre F; Ben Ali Z; Tron C; Jezequel C; Boglione-Kerrien C; Verdier MC; Guyader D; Bellissant E
Ther Drug Monit; 2017 Aug; 39(4):305-307. PubMed ID: 28700519
[TBL] [Abstract][Full Text] [Related]
19. Ombitasvir/paritaprevir/ritonavir plus dasabuvir combination in the treatment of chronic HCV infection.
Łucejko M; Parfieniuk-Kowerda A; Flisiak R
Expert Opin Pharmacother; 2016 Jun; 17(8):1153-64. PubMed ID: 27064432
[TBL] [Abstract][Full Text] [Related]
20. Effect of co-medications on paritaprevir, ritonavir, ombitasvir, dasabuvir and ribavirin pharmacokinetics: analysis of data from seven Phase II/III trials.
Polepally AR; Badri PS; Parikh A; Rodrigues L; Da Silva-Tillmann BA; Mensing S; Podsadecki TJ; Awni WM; Dutta S; Menon RM
Antivir Ther; 2016; 21(8):707-714. PubMed ID: 27584548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
